[vc_row el_class=\”fullhight\”][vc_column width=\”1/3\” text_align=\”center\”][vc_single_image image=\”6643\” img_size=\”large\” alignment=\”center\” style=\”vc_box_outline\” onclick=\”link_image\” css_animation=\”none\” lightbox=\”yes\” hover_effect=\”yes\” css=\”.vc_custom_1525507034488{margin-bottom: 2px !important;padding-bottom: 2px !important;}\”][porto_lightbox_container type=\”inline\”][porto_lightbox display=\”block\” lightbox_size=\”lg\” text=\”Repaglinide\” animation_type=\”fadeIn\” el_class=\”product-title\”][vc_row_inner css=\”.vc_custom_1517296936262{margin-top: 10px !important;margin-bottom: 1px !important;padding-top: 10px !important;padding-bottom: 2px !important;}\”][vc_column_inner width=\”1/2\”][vc_text_separator title=\”Repaglinide\” element=\”h5\”][vc_column_text css_animation=\”fadeIn\”] Dosage Forms:
- 0.5 mg, 1 mg and 2 mg tablets
[/vc_column_text][/vc_column_inner][vc_column_inner width=\”1/2\” css=\”.vc_custom_1517390616588{margin-top: 1px !important;margin-bottom: 1px !important;padding-top: 1px !important;padding-bottom: 1px !important;}\”][porto_block name=\”repaglinide\”][/vc_column_inner][/vc_row_inner][vc_row_inner el_class=\”my-popup\”][vc_column_inner][porto_blockquote footer_before=\”Anti-Diabetic drugs\” color=\”#8224e3\” animation_type=\”fadeInDown\”]Drug Group[/porto_blockquote][porto_blockquote footer_before=\”Repaglinide is an oral blood glucose-lowering drug of the meglitinide class used in the management of type 2 diabetes mellitus (also known as non-insulin dependent diabetes mellitus or NIDDM). Repaglinide lowers blood glucose levels by stimulating the release of insulin from the pancreas. This action is dependent upon functioning beta cells in the pancreatic islets.\” color=\”#81d742\” animation_type=\”fadeInDown\”]Mechanism[/porto_blockquote][porto_blockquote footer_before=\”Repaglinide is indicated as an adjunct to diet and exercise to lower the blood glucose in patients with type 2 diabetes mellitus (NIDDM) whose hyperglycemia cannot be controlled satisfactorily by diet and exercise alone.\” color=\”#1e73be\” animation_type=\”fadeInDown\”]Indications[/porto_blockquote][vc_column_text css_animation=\”fadeInDown\” css=\”.vc_custom_1525507167529{padding-bottom: 10px !important;}\”]Dosage and Administration:
- Repaglinide is given by mouth up to 30 minutes before meals, in usual initial doses of 0.5 mg; initial doses of 1 or 2 mg are usually given to patients who have had previous hypoglycaemic treatment. The dose may be adjusted, at intervals of 1 to 2 weeks, up to a maximum of 4 mg before meals; a total of 16 mg daily should not be exceeded. Repaglinide is also given with metformin or a thiazolidinedione in type 2 diabetes not adequately controlled by metformin alone.
[/vc_column_text][porto_blockquote footer_before=\”Repaglinide is not indicated for use in combination with NPH-insulin. All oral blood glucose-lowering drugs are capable of producing hypoglycemia. Proper patient selection, dosage, and instructions to the patients are important to avoid hypoglycemic episodes. Hepatic insufficiency may cause elevated Repaglinide blood levels and may diminish gluconeogenic capacity, both of which increase the risk of serious hypoglycemia. Elderly, debilitated, or malnourished patients and those with adrenal, pituitary, hepatic or severe renal insufficiency may be particularly susceptible to the hypoglycemic action of glucose-lowering drugs. When a patient stabilized on any diabetic regimen is exposed to stress such as fever, trauma, infection, or surgery, a loss of glycemic control may occur. At such times, it may be necessary to discontinue Repaglinide and administer insulin.\” color=\”#dd3333\” animation_type=\”fadeInDown\”]Precautions and Warnings[/porto_blockquote][porto_blockquote footer_before=\”The followings are the only clinical adverse reactions considered possibly: Hypoglycemia, URI, Sinusitis, Rhinitis, Bronchitis, nausea, diarrhea, constipation, vomiting, dyspepsia, arthralgia, back pain, headache, paresthesia, chest pain, urinary tract infection, tooth disorder, allergy, serious CV events, and cardiac ischemic events.\” color=\”#eeee22\” animation_type=\”fadeInDown\”]Side Effects[/porto_blockquote][ultimate_ctation content_alignment=\”ctaction-text-left\” ctaction_background_hover=\”#3d5535\” ctaction_padding_top=\”30\” ctaction_padding_bottom=\”2\” ctaction_padding_left=\”10\” ctaction_padding_right=\”20\” text_font_size=\”desktop:15px;\” el_class=\”justify\”]Interactions: In vitro data indicate that repaglinide metabolism may be inhibited by antifungal agents like ketoconazole and miconazole, and antibacterial agents like erythromycin. Drugs that induce the cytochrome P450 enzyme system 3A4 may increase repaglinide metabolism; such drugs include rifampin, barbiturates, and carbamezepine. In vivo data from a study that evaluated the co-administration of gemfibrozil with Repaglinide in healthy subjects resulted in a significant increase in repaglinide blood levels.[/ultimate_ctation][porto_blockquote footer_before=\”Pregnancy category C. Repaglinide should be used during pregnancy only if it is clearly needed. Repaglinide should be discontinued in nursing mothers, or if mothers should discontinue nursing.\” color=\”#dd9933\” animation_type=\”fadeInDown\”]Pregnancy and Lactation[/porto_blockquote][vc_column_text]Packaging
- HDPE flacons of 100’s.
[/vc_column_text][/vc_column_inner][/vc_row_inner][/porto_lightbox][/porto_lightbox_container][/vc_column][/vc_row]